|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dehm SM and Tindall DJ: Androgen receptor
structural and functional elements: role and regulation in prostate
cancer. Mol Endocrinol. 21:2855–2863. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Buchanan G, Irvine RA, Coetzee GA and
Tilley WD: Contribution of the androgen receptor to prostate cancer
predisposition and progression. Cancer Metastasis Rev. 20:207–223.
2001. View Article : Google Scholar
|
|
5
|
Agoulnik IU and Weigel NL: Androgen
receptor action in hormone-dependent and recurrent prostate cancer.
J Cell Biochem. 99:362–372. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Taplin ME and Balk SP: Androgen receptor:
a key molecule in the progression of prostate cancer to hormone
independence. J Cell Biochem. 91:483–490. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Feldman BJ and Feldman D: The development
of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45.
2001. View
Article : Google Scholar
|
|
8
|
Pienta KJ and Bradley D: Mechanisms
underlying the development of androgen-independent prostate cancer.
Clin Cancer Res. 12:1665–1671. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen Y, Sawyers CL and Scher HI: Targeting
the androgen receptor pathway in prostate cancer. Curr Opin
Pharmacol. 8:440–448. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Knudsen KE and Scher HI: Starving the
addiction: new opportunities for durable suppression of AR
signaling in prostate cancer. Clin Cancer Res. 15:4792–4798. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Eder IE, Culig Z, Ramoner R, Thurnher M,
Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G and Klocker H:
Inhibition of LncaP prostate cancer cells by means of androgen
receptor antisense oligonucleotides. Cancer Gene Ther. 7:997–1007.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zegarra-Moro OL, Schmidt LJ, Huang H and
Tindall DJ: Disruption of androgen receptor function inhibits
proliferation of androgen-refractory prostate cancer cells. Cancer
Res. 62:1008–1013. 2002.PubMed/NCBI
|
|
13
|
Wright ME, Tsai MJ and Aebersold R:
Androgen receptor represses the neuroendocrine transdifferentiation
process in prostate cancer cells. Mol Endocrinol. 17:1726–1737.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen CD, Welsbie DS, Tran C, et al:
Molecular determinants of resistance to antiandrogen therapy. Nat
Med. 10:33–39. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hååg P, Bektic J, Bartsch G, Klocker H and
Eder IE: Androgen receptor down regulation by small interference
RNA induces cell growth inhibition in androgen sensitive as well as
in androgen independent prostate cancer cells. J Steroid Biochem
Mol Biol. 96:251–258. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Compagno D, Merle C, Morin A, Gilbert C,
Mathieu JR, Bozec A, Mauduit C, Benahmed M and Cabon F:
SIRNA-directed in vivo silencing of androgen receptor inhibits the
growth of castration-resistant prostate carcinomas. PLoS One.
2:e10062007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Di Giacomo G, Koss M, Capellini TD,
Brendolan A, Pöpperl H and Selleri L: Spatio-temporal expression of
Pbx3 during mouse organogenesis. Gene Expr Patterns. 6:747–757.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lichtenauer UD, Duchniewicz M, Kolanczyk
M, et al: Pre-B-cell transcription factor 1 and steroidogenic
factor 1 synergistically regulate adrenocortical growth and
steroidogenesis. Endocrinology. 148:693–704. 2007. View Article : Google Scholar
|
|
19
|
Carleton M, Cleary MA and Linsley PS:
MicroRNAs and cell cycle regulation. Cell Cycle. 6:2127–2132. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schmittgen TD: Regulation of microRNA
processing in development, differentiation and cancer. J Cell Mol
Med. 12:1811–1819. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ambros V: MicroRNA pathways in flies and
worms: growth, death, fat, stress and timing. Cell. 113:673–676.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
96(Suppl): R40–R44. 2007.PubMed/NCBI
|
|
24
|
Wiemer EA: The role of microRNAs in
cancer: no small matter. Eur J Cancer. 43:1529–1544. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takahashi Y, Forrest AR, Maeno E,
Hashimoto T, Daub CO and Yasuda J: Mir-107 and mir-185 can induce
cell cycle arrest in human non small cell lung cancer cell lines.
PLoS One. 4:e66772009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Imam JS, Buddavarapu K, Lee-Chang JS,
Ganapathy S, Camosy C, Chen Y and Rao MK: MicroRNA-185 suppresses
tumor growth and progression by targeting the six1 oncogene in
human cancers. Oncogene. 29:4971–4979. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu M, Lang N, Chen X, et al: MiR-185
targets RhoA and Cdc42 expression and inhibits the proliferation
potential of human colorectal cells. Cancer Lett. 301:151–160.
2011. View Article : Google Scholar
|
|
28
|
Akçakaya P, Ekelund S, Kolosenko I, et al:
MiR-185 and miR-133b deregulation is associated with overall
survival and metastasis in colorectal cancer. Int J Oncol.
39:311–318. 2011.PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
30
|
Akao Y, Nakagawa Y and Naoe T: let-7
microRNA functions as a potential growth suppressor in human colon
cancer cells. Biol Pharm Bull. 9:903–906. 2006. View Article : Google Scholar
|
|
31
|
Majid S, Dar AA, Saini S, et al: miR-23b
represses proto-oncogene Src kinase and functions as
methylation-silenced tumor suppressor with diagnostic and
prognostic significance in prostate cancer. Cancer Res.
72:6435–6446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ni Y, Meng L, Wang L, Dong W, Shen H, Wang
G, Liu Q and Du J: MicroRNA-143 functions as a tumor suppressor in
human esophageal squamous cell carcinoma. Gene. 517:197–204. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu N, Lin X, Zhao X, Zheng L, Xiao L, Liu
J, Ge L and Cao S: MiR-125b acts as an oncogene in glioblastoma
cells and inhibits cell apoptosis through p53 and
p38MAPK-independent pathways. Br J Cancer. 109:2853–2863. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang B, Pan X, Cobb GP and Anderson TA:
MicroRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12.
2007. View Article : Google Scholar
|
|
35
|
Liu H, Brannon AR, Reddy AR, et al:
Identifying mRNA targets of microRNA dysregulated in cancer: with
application to clear cell renal cell carcinoma. BMC Syst Biol.
4:512010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Abaan OD and Toretsky JA: PTPl1: a large
phosphatase with a split personality. Cancer Metastasis Rev.
27:205–214. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mangelsdorf DJ, Thummel C, Beato M, et al:
The nuclear receptor superfamily: the second decade. Cell.
83:835–839. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Heinlein CA and Chang C: Androgen receptor
(AR) coregulators: an overview. Endocr Rev. 23:175–200. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chmelar R, Buchanan G, Need EF, Tilley W
and Greenberg NM: Androgen receptor coregulators and their
involvement in the development and progression of prostate cancer.
Int J Cancer. 120:719–733. 2007. View Article : Google Scholar
|
|
40
|
Chen S, Song CS, Lavrovsky Y, Bi B,
Vellanoweth R, Chatterjee B and Roy AK: Catalytic cleavage of the
androgen receptor messenger RNA and functional inhibition of
androgen receptor activity by a hammerhead ribozyme. Mol
Endocrinol. 12:1558–1566. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Eder IE, Hoffmann J, Rogatsch H, Schafer
G, Zopf D, Bartsch G and Klocker H: Inhibition of LNCaP prostate
tumor growth in vivo by an antisense oligonucleotide directed
against the human androgen receptor. Cancer Gene Ther. 9:117–125.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cheng H, Snoek R, Ghaidi F, Cox ME and
Rennie PS: Short hairpin RNA knockdown of the androgen receptor
attenuates ligand independent activation and delays tumor
progression. Cancer Res. 66:10613–10620. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liao X, Tang S, Thrasher JB, Griebling TL
and Li B: Small-interfering RNA-induced androgen receptor silencing
leads to apoptotic cell death in prostate cancer. Mol Cancer Ther.
4:505–515. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lim AC and Attard G: Improved therapeutic
targeting of the androgen receptor: rational drug design improves
survival in castration-resistant prostate cancer. Curr Drug
Targets. 14:408–419. 2013. View Article : Google Scholar : PubMed/NCBI
|
